【Medical Devices | Lepu Diagnostics Implements Fuller's WMS to Achieve Digital Transformation of Supply Chain Management】

Summary: Recently, Beijing Lepu Diagnostics Technology Co., Ltd. partnered with Fuller to implement the FLUX WMS solution, enabling lean management across all materials and processes and enhancing its digital supply chain management capabilities. Beijing Lepu Diagnostics Technology Co., Ltd. (hereinafter referred to as “Lepu Diagnostics”) was founded in 2008 and specializes in the research & development, manufacturing, sales, and service of in vitro diagnostic (IVD) products. Its product portfolio covers multiple lines including point-of-care testing (POCT), thromboelastography, blood typing cards, electrochemistry, clinical chemistry, and chemiluminescence assays. Among these, the POCT and thromboelastography series have matured into industry-leading product lines. The company’s subsidiaries include Yantai Aidekang Biotechnology Co., Ltd., Lepu (Beijing) Diagnostics Technology Co., Ltd. (Lepu Clinical Chemistry), Beijing Aipuyi Biotechnology Co., Ltd., and Beijing Lepu Smart Healthcare Technology Co., Ltd. The company possesses strong technical and R&D capabilities, supported by professional teams in IVD R&D, manufacturing, and quality assurance. It has obtained over one hundred product registration certificates, multiple national patents, and CE certifications, and is recognized by relevant Chinese authorities as a high-tech enterprise. Lepu Diagnostics operates GMP-compliant Class 10,000 cleanroom production facilities and has achieved certification under CMD ISO 13485 and CMD ISO 9001 quality management systems.

【Medical Devices | Bosun Biotech Implements Fuller's Solution to Achieve Digital Transformation of Supply Chain Management】

Summary: Recently, Zhejiang Bosun Biotechnology Co., Ltd. signed an agreement with Fuller to implement the FLUX WMS solution, enabling lean management across the entire material lifecycle and enhancing its digital supply chain management capabilities. As a leading provider of comprehensive solutions for congenital birth defect prevention and control in China, Bosun Biotech has been a pioneer and practitioner in this field since its establishment in 2003. To date, it has delivered professional, customized birth defect prevention and control solutions to more than 700 centers nationwide—including birth defect prevention and control centers, newborn screening centers, prenatal diagnosis centers, and prenatal screening institutions—continuously creating value for clients. Cumulatively, it has conducted over 100 million screenings, empowered over 30,000 families carrying fetuses with congenital defects to make informed reproductive choices, and enabled the diagnosis and provision of appropriate treatment and medical support for over 50,000 newborns affected by inherited metabolic disorders. Customer-centric, Bosun Biotech has progressively built an integrated industrial chain spanning R&D, product manufacturing, clinical testing, and birth defect consulting services.

H.B. Fuller Bids on Advanced Medical Solutions

Jun 30, 2026

H.B. Fuller has launched a recommended cash offer to acquire Advanced Medical Solutions Group, aiming to expand its medical adhesives portfolio and market presence. The deal combines AMS's surgical adhesive technologies with H.B. Fuller's infrastructure to drive revenue synergies.

Nonwovens Industry -

2026-05-26

Activist Ancora Pushes H.B. Fuller to Drop Bid for UK’s AMS

2026-05-26

Cleveland-based activist Ancora pushes H.B. Fuller to drop bid for U.K. firm

2026-05-26

Ancora Urges H.B. Fuller to Abandon Pursuit of Advanced Medical Solutions Acquisition

2026-05-28

H.B. Fuller Announces New Coating to Improve Food Packaging Recyclability

2026-05-30

Activist Investor Ancora Urges HB Fuller to Abandon UK AMS Acquisition Bid